A comparison of repeated low-level red light and low-dose atropine for myopia control: A two-year retrospective study

IF 2.6 3区医学 Q2 ONCOLOGY

Photodiagnosis and Photodynamic Therapy Pub Date : 2025-08-06 DOI:10.1016/j.pdpdt.2025.104754

Mingming Zhang , Yinghui Shi , Yuexin Wang , Yangguang Li , Jian Qin , Xiaobing Wang , Ying Jie

{"title":"A comparison of repeated low-level red light and low-dose atropine for myopia control: A two-year retrospective study","authors":"Mingming Zhang , Yinghui Shi , Yuexin Wang , Yangguang Li , Jian Qin , Xiaobing Wang , Ying Jie","doi":"10.1016/j.pdpdt.2025.104754","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To compare the long-term efficacy between repeated low-level red light (RLRL) therapy and low-dose atropine (LDA) eye drops for myopia control.</div></div><div><h3>Methods</h3><div>Treatment naïve myopic children receiving RLRL or LDA therapy were retrospectively included. The spherical equivalent (SE) and axial length (AL) were evaluated at baseline and 6-, 12-, and 24-month follow-up. The myopia progression and regression were compared between groups.</div></div><div><h3>Results</h3><div>In total, 122 myopic children were enrolled. The SE progression and AL elongation were significantly less in the RLRL than in the LDA group at 6 months (<em>P</em> = 0.002, SE; <em>P</em> = 0.004, AL), 12 months (<em>P</em> < 0.001) and 24 months (<em>P</em> < 0.001). For patients with RLRL, the SE progression was greater during the second than the first year (<em>P</em> = 0.05). The proportion of patients with SE regression in the RLRL group was greater than that in the LDA group at 12 months (<em>P</em> = 0.003), and the AL shortening proportion was significantly greater in the RLRL group than in the LDA group at 6 months (<em>P</em> = 0.001), 12 months (<em>P</em> = 0.001), and 24 months (<em>P</em> = 0.049). Eight adverse events were reported in the RLRL group without irreversible structural damage.</div></div><div><h3>Conclusion</h3><div>The present research demonstrates that RLRL treatment is more effective than 0.01 % atropine in delaying myopia progression and observes a greater percentage of patients with SE regression and AL shortening in myopic children over two years.</div></div>","PeriodicalId":20141,"journal":{"name":"Photodiagnosis and Photodynamic Therapy","volume":"55 ","pages":"Article 104754"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Photodiagnosis and Photodynamic Therapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1572100025002868","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To compare the long-term efficacy between repeated low-level red light (RLRL) therapy and low-dose atropine (LDA) eye drops for myopia control.

Methods

Treatment naïve myopic children receiving RLRL or LDA therapy were retrospectively included. The spherical equivalent (SE) and axial length (AL) were evaluated at baseline and 6-, 12-, and 24-month follow-up. The myopia progression and regression were compared between groups.

Results

In total, 122 myopic children were enrolled. The SE progression and AL elongation were significantly less in the RLRL than in the LDA group at 6 months (P = 0.002, SE; P = 0.004, AL), 12 months (P < 0.001) and 24 months (P < 0.001). For patients with RLRL, the SE progression was greater during the second than the first year (P = 0.05). The proportion of patients with SE regression in the RLRL group was greater than that in the LDA group at 12 months (P = 0.003), and the AL shortening proportion was significantly greater in the RLRL group than in the LDA group at 6 months (P = 0.001), 12 months (P = 0.001), and 24 months (P = 0.049). Eight adverse events were reported in the RLRL group without irreversible structural damage.

Conclusion

The present research demonstrates that RLRL treatment is more effective than 0.01 % atropine in delaying myopia progression and observes a greater percentage of patients with SE regression and AL shortening in myopic children over two years.

查看原文本刊更多论文

重复低强度红光与低剂量阿托品控制近视的比较：一项两年回顾性研究。

目的：比较重复低水平红光（RLRL）治疗与低剂量阿托品（LDA）滴眼液控制近视的远期疗效。方法：回顾性分析naïve接受RLRL或LDA治疗的近视儿童。在基线和6个月、12个月和24个月的随访中评估球形当量（SE）和轴向长度（AL）。比较两组近视的进展和消退情况。结果：共纳入122名近视儿童。6个月时，RLRL组的SE进展和AL伸长明显低于LDA组(P = 0.002，SE；P = 0.004，AL)、12个月（P < 0.001）、24个月（P < 0.001）。对于RLRL患者，SE进展在第二年大于第一年（P = 0.05）。RLRL组在12个月时出现SE退化的患者比例大于LDA组（P = 0.003），在6个月（P = 0.001）、12个月（P = 0.001）、24个月（P = 0.049）时，RLRL组AL缩短的比例显著高于LDA组（P = 0.003）。RLRL组报告8例不良事件，无不可逆结构损伤。结论：本研究表明，RLRL治疗在延缓近视进展方面比0.01%阿托品更有效，2年内近视儿童中SE消退和AL缩短的比例更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Photodiagnosis and Photodynamic Therapy ONCOLOGY-

CiteScore

5.80

自引率

24.20%

发文量

509

审稿时长

50 days

期刊介绍： Photodiagnosis and Photodynamic Therapy is an international journal for the dissemination of scientific knowledge and clinical developments of Photodiagnosis and Photodynamic Therapy in all medical specialties. The journal publishes original articles, review articles, case presentations, "how-to-do-it" articles, Letters to the Editor, short communications and relevant images with short descriptions. All submitted material is subject to a strict peer-review process.